Elevara Medicines Secures $70M Series A To Advance RA And Inflammatory Disease Therapies

The round was co-led by Forbion and Sofinnova Partners, with participation from founding investor Monograph Capital. The funds will support a Phase 2 clinical trial of Elevara’s lead candidate, ELV001, and exploratory programs in additional inflammatory and women’s health conditions.

The upcoming START-SYNERGY Phase 2 trial will enroll around 180 RA patients who have shown inadequate response to methotrexate and TNF inhibitors, with recruitment expected to start before the end of 2025.

Read Also - Kotcha Raises €3.5M To Scale Its AI-Powered Coaching Platform For Runners

“We have created Elevara together with Monograph Capital because we believe ELV001 could have a fundamental impact on RA patients who fail to achieve disease remission through immune targeted approaches,” said Elevara CEO Emma Tinsley, who also heads up Weatherden. “This $70 million financing provides us with the resources to rapidly advance ELV001 through Phase 2 and to expand into other chronic inflammatory indications.”

Co-founded by Weatherden and supported by Monograph Capital, Elevara is led by CEO Emma Tinsley and CMO Professor Dominique Baeten, MD, PhD. Its lead program, ELV001, is a first-in-class oral CDK4/6 inhibitor positioned as an add-on therapy for RA patients with incomplete response to TNF inhibitors offering a new approach to reduce dependency on multiple immunosuppressive treatments.

Elevara Medicines has secured exclusive global rights from Teijin Pharma, part of the Teijin Group (TSE: 3401), to develop, manufacture, and commercialize ELV001 a program backed by over a decade of scientific research.

The company’s board of directors includes Emma Tinsley (CEO, Elevara), Tim Funnell (Monograph Capital), Vanessa Carle (Forbion), Maina Bhaman (Sofinnova Partners), and Gijs van den Brink (Independent Director).

“The current standard of care isn’t achieving low disease activity and remission in a large proportion of patients with RA,” said Elevara’s Chief Medical Officer Professor Dominique Baeten. “Teijin has built an exceptional data package of preclinical and clinical work with the highest level of scientific rigor and discipline. By targeting the synovial fibroblast rather than immune cells, ELV001 is uniquely positioned to work with approved immunomodulators for RA in early line therapy.”

About Elevara Medicines

Elevara Medicines is a London-based clinical-stage biotech developing innovative therapies for rheumatoid arthritis and chronic inflammatory diseases. Its lead candidate ELV001, is a first-in-class oral CDK4/6 inhibitor designed as an add-on therapy for patients with inadequate response to existing treatments, aiming to improve outcomes and reduce reliance on multiple immunosuppressive drugs.